Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc. (WHWK): 5 pipeline candidates · 1 upcoming catalyst · ~16 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.1 months
D/E 0.10 · 47% dilution
Lead: Phase 2
5 candidates
1 upcoming, next in ~5246d
0 buys · 14 sells (180d)
A transparent, data-derived signal for Whitehawk Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$208.7M
Cash
$34.8M
Quarterly Burn
$22.2M
Runway
16.1 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| fyarro | Phase 2 |
| fyarro + adagrasib | Preclinical |
| hwk-007 | Phase 1 |
| hwk-016 | Phase 1 |
| hwk-206 | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$87.9M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 4,166,000 | $14.4M |
| suvretta capital management, llc | 3,700,000 | $12.8M |
| acuta capital partners, llc | 3,410,402 | $11.8M |
| vanguard capital management llc | 2,631,540 | $9.1M |
| kvp capital advisors, lp | 2,165,997 | $7.5M |
| stempoint capital lp | 1,878,738 | $6.5M |
| acorn capital advisors, llc | 1,139,363 | $3.9M |
| ally bridge group (ny) llc | 817,939 | $2.8M |
| woodline partners lp | 562,994 | $1.9M |
| balyasny asset management l.p. | 550,441 | $1.9M |
Showing top 10 of 58 institutional holders of Whitehawk Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Whitehawk Therapeutics, Inc.'s pipeline?
Whitehawk Therapeutics, Inc. (WHWK) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Whitehawk Therapeutics, Inc.'s lead drug candidate?
Whitehawk Therapeutics, Inc.'s most advanced tracked candidate is fyarro (Phase 2) for Neuroendocrine tumors (NETs) of the GI tract, lung, or pancreas.
What is Whitehawk Therapeutics, Inc.'s next catalyst?
Whitehawk Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FYARRO" — expected October 28, 2040.
What is Whitehawk Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Whitehawk Therapeutics, Inc. has approximately 16.1 months of cash runway.
What is Whitehawk Therapeutics, Inc.'s market capitalization?
Whitehawk Therapeutics, Inc.'s market capitalization is approximately $208.7M.
Get the full picture on Whitehawk Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.